GlobeNewsWire
26 Mar 2026, 20:05 UTC · 29w ago
Impact · against what's priced in
Zentalis Pharmaceuticals has provided a clear roadmap for 2026, with the market now pricing in a year of high-stakes clinical catalysts. The primary value drivers are the anticipated topline DENALI Part 2 results and the initiation of the Phase 3 ASPENOVA trial.
No priced-in read yet
What the story claims
3 claims · scored −1 bearish … +1 bullish
Topline results from the DENALI Part 2 trial, which could potentially support accelerated FDA approval for azenosertib, are expected by year-end 2026.
More positive than 99% of claims this week
Zentalis expects to initiate the ASPENOVA randomized Phase 3 confirmatory trial in the first half of 2026.
Continue reading
5 related stories
The company has set a concrete timeline for azenosertib, with dose confirmation in H1 2026 and a potential accelerated approval-supporting readout from the DENALI Part 2 trial by year-end 2026.
Read from the article alone
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 88% of claims this week
Dose confirmation for the DENALI Part 2a study is expected in the first half of 2026 following the completion of enrollment.
More positive than 69% of claims this week
Which stocks this story touches
More positive than 79% of ticker scores this week
The company reported completion of a key clinical trial enrollment and has a strong pipeline of milestones and potential accelerated approval for its lead candidate in 2026.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
3h ago
The Motley Fool
4h ago
−20.2%
Price is moving against the score
$2.13 vs $2.67 close before publication (Mar 26) · not market-adjusted
ZNTL chart →
